For help on how to get the results you want, see our search tips.
348 results
Categories
Human Remove Human filter
Medicine
Paediatric investigation plans Remove Paediatric investigation plans filter
Orphan designations Remove Orphan designations filter
Medicine type
Orphan medicine Remove Orphan medicine filter
-
List item
Orphan designation: Talquetamab for: Treatment of multiple myeloma (updated)
Date of designation: 20/08/2021, Positive, Last updated: 21/09/2023 -
List item
Orphan designation: N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt for: Treatment of acute myeloid leukaemia (updated)
Date of designation: 23/03/2009, Positive, Last updated: 15/09/2023 -
List item
Orphan designation: Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) for: Treatment of hypoparathyroidism (updated)
Date of designation: 19/10/2020, Positive, Last updated: 15/09/2023 -
List item
Orphan designation: Dabrafenib mesylate for: Treatment of glioma (updated)
Date of designation: 09/12/2020, Positive, Last updated: 15/09/2023 -
List item
Orphan designation: Ganaxolone for: Treatment of CDKL5 deficiency disorder
Date of designation: 13/11/2019, Positive, Last updated: 31/07/2023 -
List item
Orphan designation: edaravone for: Treatment of amyotrophic lateral sclerosis
Date of designation: 19/06/2015, Positive, Last updated: 21/07/2023 -
List item
Orphan designation: Glofitamab for: Treatment of diffuse large B-cell lymphoma
Date of designation: 15/10/2021, Positive, Last updated: 18/07/2023 -
List item
Orphan designation: Recombinant human acid sphingomyelinase (also known as olipudase alfa) for: Treatment of Niemann-Pick disease
Date of designation: 24/06/2022, Positive, Last updated: 18/07/2023 -
List item
Orphan designation: (1R,2R)-octanoic acid[2-(2',3'-dihydro-benzo[1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid salt (eliglustat) for: Treatment of Gaucher disease
Date of designation: 04/12/2007, Positive, Last updated: 18/07/2023 -
List item
Orphan designation: Humanised IgG4 monoclonal antibody against total complement component 1, subcomponent s (sutimlimab) for: Treatment of autoimmune haemolytic anaemia
Date of designation: 17/02/2016, Positive, Last updated: 18/07/2023 -
List item
Orphan designation: Cyclic pyranopterin monophosphate (fosdenopterin) for: Treatment of molybdenum-cofactor deficiency type A
Date of designation: 20/09/2010, Positive, Last updated: 17/07/2023 -
List item
Orphan designation: Cedazuridine, decitabine for: Treatment of acute myeloid leukaemia
Date of designation: 10/12/2021, Withdrawn, Last updated: 06/07/2023 -
List item
Orphan designation: tasimelteon for: Treatment of non-24-hour sleep-wake disorders in blind people with no light perception
Date of designation: 23/02/2011, Positive, Last updated: 30/06/2023 -
List item
Orphan designation: Autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene for: Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency
Date of designation: 26/08/2005, Positive, Last updated: 27/06/2023 -
List item
Orphan designation: Cannabidiol for: Treatment of tuberous sclerosis
Date of designation: 17/01/2018, Positive, Last updated: 15/06/2023 -
List item
Orphan designation: Cannabidiol for: Treatment of Lennox-Gastaut syndrome
Date of designation: 20/03/2017, Positive, Last updated: 14/06/2023 -
List item
Orphan designation: Cannabidiol for: Treatment of Dravet syndrome
Date of designation: 15/10/2014, Positive, Last updated: 14/06/2023 -
List item
Orphan designation: Sirolimus for: Treatment of tuberous sclerosis
Date of designation: 23/08/2017, Positive, Last updated: 09/06/2023 -
List item
Orphan designation: Ivosidenib for: Treatment of biliary tract cancer
Date of designation: 21/03/2018, Positive, Last updated: 12/05/2023 -
List item
Orphan designation: Ivosidenib for: Treatment of acute myeloid leukaemia
Date of designation: 12/12/2016, Positive, Last updated: 12/05/2023 -
List item
Orphan designation: 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor) for: Treatment of sickle cell disease
Date of designation: 18/11/2016, Positive, Last updated: 04/05/2023 -
List item
Orphan designation: Lutetium (177Lu)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide (lutetium (177Lu) oxodotreotide) for: Treatment of gastro-entero-pancreatic neuroendocrine tumours
Date of designation: 31/01/2008, Positive, Last updated: 03/05/2023 -
List item
Orphan designation: Gallium (68Ga)-edotreotide for: Diagnosis of gastro-entero-pancreatic neuroendocrine tumours
Date of designation: 19/03/2015, Positive, Last updated: 03/05/2023 -
List item
Orphan designation: Fenfluramine hydrochloride for: Treatment of Lennox-Gastaut syndrome
Date of designation: 27/02/2017, Positive, Last updated: 25/04/2023 -
List item
Orphan designation: Fenfluramine hydrochloride for: Treatment of Dravet syndrome
Date of designation: 18/12/2013, Positive, Last updated: 25/04/2023